Rakesh Jhunjhunwala invested company under SFIO gaze over charges of cheating, diversion of funds

The corporate affairs ministry ordered a probe after RoC found that the company allegedly diverted Rs 1,000 crore and also failed to pay Rs 150 crore in interest.

The Ministry of Corporate Affairs (MCA) has ordered the Serious Fraud Investigation Office (SFIO) to investigate the charges of cheating and diversion of funds amounting to more than Rs 1,000 crore by Bilcare Ltd, a company in which ace Investor Rakesh Jhunjhunwala recently invested.

Bilcare was in the news recently after Jhunjhunwala made Rs 13 lakh daily from the stock in 69 sessions since March 23, 2020.

The Registrar of Companies (RoC) has already conducted one round of inquiry against the Pune-based company and submitted a report to the ministry.

“The RoC found that the company, in the last six years, has accepted deposits from public/shareholders amounting to about Rs 350 crore and failed to pay interest amount to the tune of about Rs 150 crore as on March 31, 2019, to thousands of deposit holders,” a source told Moneycontrol.

“The company has also diverted more than Rs 1,000 crore as investments, and loans and advances to foreign subsidiaries in Mauritius, Germany, Italy and Singapore. It has made investments amounting to about Rs 500 crore in wholly-owned subsidiaries like Bilcare Singapore Pte Limited. The entire amount was lost after the Singapore High Court ordered the liquidation of the subsidiary," the source said.

The RoC initiated the inquiry after receiving complaints from many deposit holders.

Confirming the SFIO probe, a source in the ministry said, "Continuing its action against companies which raise deposits from public and siphon off funds, the ministry has ordered an SFIO investigation into the affairs of Bilcare Ltd.”

Bilcare deals in pharma packaging solutions and clinical material supplies for new drug discovery projects.

Bilcare has been paying interest on time to all deposit holders, even during COVID-19, company sources said. “The company is responding to the letter from SFIO with appropriate advice from its advocates,” they said.

“Another observation in the RoC report is that the company has taken huge loans amounting to about Rs 714.37 crore from various banks from time to time and has defaulted on repayments. The company owes about Rs 2,000 crore to banks in India and abroad. These banks have declared Bilcare as a non-performing asset (NPA)," another source said.

The SFIO may also investigate the role of the statutory auditor in this case.

Source: Moneycontrol.com

Comments

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...

SD Solutions

Search This Blog